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Background. To our knowledge, the hormone receptor status of noncontiguous ductal carcinoma in situ (DCIS) occurring
concurrently in ER/PgR-negative invasive cancer has not been studied. The current study was undertaken to investigate the
ER/PgR receptor status of DCIS of the breast in patients with ER/PgR-negative invasive breast cancer. Methods. We reviewed
the immunohistochemical (IHC) staining for ER and PgR of 187 consecutive cases of ER/PgR-negative invasive breast cancers,
collected from 1995 to 2002. To meet the criteria for the study, we evaluated ER/PgR expression of DCIS cancer outside of the
invasive breast cancer. Results. A total of 37 cases of DCIS meeting the above criteria were identiﬁed. Of these, 16 cases (43.2%)
showed positive staining for ER, PgR, or both. Conclusions. In our study of ER/PgR-negative invasive breast cancer we found that
in 8% of cases noncontiguous ER/PR-positive DCIS was present. In light of this ﬁnding, it may be important for pathologists
to evaluate the ER/PgR status of DCIS occurring in the presence of ER/PgR-negative invasive cancer, as this subgroup could be
considered for chemoprevention.
1.Introduction
Breast cancer evolves from normal epithelium of the ter-
minal duct or lobular unit through a series of increas-
ingly abnormal proliferative lesions beginning with atypical
hyperplasia, to premalignant in situ disease, to malignant
and increasingly invasive neoplasia [1–3]. In situ carcinoma
is characteristically contained within the epithelium, with
the basement membrane intact, and without any signs of
invasion [4]. Ductal carcinoma in situ (DCIS) is probably
a continuum of successive steps of the same process, with
increasing malignant potential as the disease progresses from
papillary to comedo forms. DCIS originates by proliferation
of the ductal luminal cells, which form protrusions into the
lumen, called papillary DCIS [5]. These may become more
coalescent, leaving a few empty, rounded spaces, known as
cribriform DCIS. When the lumen is ﬁlled with proliferating
cells, it becomes completely obliterated, termed as solid
DCIS. Central areas of these ducts undergo necrosis because
of the ischemic microenvironment, which results in comedo
DCIS [4].
ER expression is generally low in normal breast epithe-
lium, except for a small peak in the ﬁrst week of the
menstrual cycle [6]. On average, 80% of atypical ductal
hyperplasias are associated with ER overexpression [7–9].
Approximately 75% of low-grade DCIS lesions express ER2 ISRN Oncology
compared to only 30% of the high-grade DCIS lesions [8–
12]. ER positivity is found in up to 60 to 70% of invasive
breast cancers [13, 14].
Expression of ER in DCIS alone compared to contiguous
DCIS associated with invasive carcinoma has been investi-
gated in the past. One study showed that intraductal carci-
noma associated with invasive cancer was more frequently
ER-positive compared to DCIS without associated invasion
[15]. There was a strong concordance of ER/PgR expression
in contiguous DCIS associated with invasive cancer (98%)
with virtually all cases being ER/PgR positive.
To our knowledge there is no literature regarding the
hormone receptor status of noncontiguous DCIS occur-
ring concurrently in ER/PgR-negative invasive cancer. The
current study was undertaken to investigate the hormonal
receptorstatusofDCISofthebreastinpatientswithER/PgR-
negative invasive breast cancer.
2.MaterialsandMethods
We reviewed ER/PgR immunohistochemical (IHC) staining
of invasive breast cancer cases performed by the pathology
department at Winthrop University Hospital from 1995 to
2003. The stain results were as follows: ER+/PgR+ = 358
cases (50.4%), ER+/PgR− = 109 cases (15.3%), ER−/PgR+
= 56 cases (7.9%), and ER−/PgR− = 187 cases (26.3%). Of
these, 187 cases of ER-negative/PgR-negative breast cancer
were the subgroup of interest for this study. For the purpose
of our study, the DCIS component for ER/PgR analyses was
required to be at least 1mm remote from the border of
invasive cancer in order to ensure noncontiguity. Cases with
DCIS only within the tumorand caseswith no residual DCIS
were excluded from the study. Given this strict inclusion
criteria, 150 women were excluded from the study. The
remaining 37 cases, representing 19.7% of the ER/PgR-
negative carcinomas and 5.2% of the total group of breast
carcinomas, were the subject of ER/PgR status of DCIS that
occurs in association with ER/PR-negative invasive breast
carcinoma. These were analyzed for ER/PgR status in the
DCIS component.
ER/PgR staining by immunohistochemistry using avidin
biotin complex methodology (ABC) with heat-induced
epitoperetrievalwasperformedonallcasesofinvasivebreast
carcinoma as a routine test to render prognostic information
to clinicians treating these patients. The control blocks for
thestudyconsistedofexternalpositiveandnegativecontrols.
The positive control had both strong and weak staining
of the DCIS component and required positive reactivity
of the benign terminal duct lobular units. In addition, all
study cases showed positive staining of benign terminal duct
lobular units. All histological sections of ER/PgR-negative
breast carcinomas were reviewed by two pathologists. The
histological evaluation of DCIS type, nuclear grade, presence
of intraductal necrosis, and DCIS ER and PgR staining and
stain intensity were evaluated. A semiquantitative scoring of
percentage of positive cells with nuclear staining was used: 0
= no staining, 1+ = 1–10% staining, 2+ = 11–50% staining,
and 3+ = >50% positive nuclear stain. Nuclear ER and PgR
stain intensity was graded as weak, moderate, or strong.
Table 1: Analysis of combined ER and PgR status of the 37 cases of
intraductal breast cancer.
Hormone Receptor status Number of patients Percentage
ER− &P g R − 21 56.7%
ER+ & PgR+ 11 29.7%
ER+ & PgR− 25 . 4 %
ER− & PgR+ 3 8.1%
The study was in compliance with the institutional
internal review board (IRB) for which we received a waiver,
as all the subjects in the study were deidentiﬁed.
3. Results
A total of 710 invasive breast cancer cases were collected and
reviewed. One hundred and eighty-seven invasive cancers
were found to be ER/PgR negative. We found a subgroup
of 37 cases that had a DCIS component at least 1mm
remote from the border of invasive cancer. These cases were
subjectedtofurtherstudy.Sixteenofthe37 ER/PgR-negative
breast cancer cases (43.2%) had a DCIS component showing
positive staining for ER, PgR, or both ER and PgR Tables 1
and 2.
Upon further analysis, the subtypes of DCIS were
identiﬁed as follows Table 3: 15 percent of cases were
comedocarcinoma and 39.4% demonstrated mixed pattern
of DCIS. Of the cases that demonstrated mixed pattern, 46%
contained comedocarcinoma along with another architec-
tural pattern of DCIS. Therefore, more than 33% of the
patients were found to have comedocarcinoma or a mixed
pattern containing comedocarcinoma, a subtype of DCIS
with poor diﬀerentiation.
A majority of the cases (60.6%) showed a high nuclear
grade Table 4. Notably, none of the cases had a low nuclear
gradeofDCIS.Alargepercentageofcasesthusdemonstrated
a high nuclear grade and poorly diﬀerentiated subtype of
DCIS suggesting that these lesions are aggressive.
4. Discussion
In this study of hormone-negative invasive breast cancer
with concurrent noncontiguous DCIS, we demonstrate that
43.2% of the cases of DCIS were hormone receptor positive.
This is in contrast to prior observations of strong concor-
dance between hormone receptor status of breast tumors
containing DCIS and contiguous invasive cancer [9, 15, 16].
In a study by Bur et al., there was a 98% correlation
between ER positivity in DCIS and the invasive component
[16]. DCIS associated with an invasive carcinoma was more
frequently ER positive than DCIS without invasion. All
cases of ER-negative DCIS showed no ER expression in
the adjacent invasive carcinoma. Barnes and Masood also
reported a concordance between ER status of DCIS and the
invasive component [9]. Immunohistochemical staining was
positive for ER in 75% of the DCIS, 73% of DCIS with
invasive cancer, and 100% of atypical hyperplasia. In 29 of 30ISRN Oncology 3
Table 2: Intensity of IHC staining of DCIS.
IHC staining ER PR
Number of patients Percent Number of patients Percent
0 25 68% 24 65%
1+ 5 14% 6 16%
2+ 2 5% 1 3%
3+ 5 14% 6 16%
Table 3: Architecture patterns of DCIS.
Mixed patterns of DCIS 39.4%
Cribriform DCIS 21.2%
Solid DCIS 18.2%
Comedocarcinoma 15.2%
Papillary DCIS 3%
Cancerized lobule 3%
cases ER expression of the DCIS concurred with that found
in the invasive component.
These studies, however, only examined DCIS that
occurred within the invasive cancer. In our study, we
examined noncontiguous DCIS at least one millimeter apart
from the invasive component. The discrepancy between
the current study and previously published ones raises the
question of whether ER positive and ER negative breast
cancers arise from distinctly separate clones as in multifocal
or multicentric disease, or evolve from one clone.
The best model for breast cancers that arise from
diﬀerent clones is the example of contralateral breast cancer.
There have been a number of studies investigating the
ER/PgR status in contralateral breast cancer [17, 18]. In
the study by Arpino et al., the ER status of the primary
breast cancer (PBC) was not related to the hormone receptor
status of the subsequent contralateral breast cancer (CBC),
suggesting that this was a stochastic stem cell event [17].
In the absence of adjuvant tamoxifen, 88% patients who
had an ER-positive PBC and 75% who had an ER-negative
PBC developed an ER-positive CBC (P = 0.11). The authors
concluded that patients with an ER-negative PBC were just
as likely to develop an ER-positive CBC as patients with
an ER-positive PBC. Opposite conclusions were drawn by
Swain et al. in another study [18]. This was a retrospective
analysis of data from National Surgical and Adjuvant Breast
and Bowel Project trials (NSABP) B-18, B-22, and B-25,
whichdemonstratedthatamongpatientswhodidnotreceive
tamoxifen, 89% with an ER-positive PBC had an ER-positive
CBC and 70% with an ER-negative primary breast cancer
had an ER-negative contralateral breast cancer (odds ratio
= 14.8, 95% P < 0.001). The authors concluded that the ER
statusofaprimarybreastcancercorrelateswiththeERstatus
of a subsequent contralateral tumor, suggesting that another
model may be operative.
It is unclear whether hormone receptor-positive and
hormone receptor-negative breast cancer are derived from
the same or from diﬀerent stem cells. The stochastic stem
Table 4: Nuclear grade of DCIS.
Nuclear grade 1 (low nuclear grade) 0%
Nuclear grade 2 (intermediate nuclear grade) 39.4%
Nuclear grade 3 (high nuclear grade) 60.6%
cellmodelwouldsupportthehormonereceptor-positiveand
hormone receptor-negative tumors derived from separate
stem cells [19, 20]. A more modern theory postulates that
ER-positive stem cells can evolve from ER-negative ones.
Liu et al. recently showed that BRCA1 regulates human
mammary stem/progenitor cell fate [21]. By using in vitro
systems and a humanized NOD/SCID mouse model, they
demonstrated that BRCA1 expression is required for the
diﬀerentiation of ER-negative stem/progenitor cells to ER-
positive luminal cells.
In our series there were no cases of low-grade DCIS.
Most of the cases of ER/PgR-positive DCIS were in the
intermediate grade. This is consistent with previously pub-
lished studies. In the study by Bur et al. the nuclear
pleomorphism was signiﬁcantly correlated with absence or
low percentage of ER staining in DCIS [16]. ER-positivity
was more likely observed in monomorphic nuclei (P <
0.001). Barnes and Masood also reported that the degree of
nuclear polymorphism was generally inversely related to ER
positivity [9].
The ﬁnding of hormone receptor-positive DCIS in as
many as 8% cases of hormone receptor-negative invasive
breast cancer raises the issue of chemoprevention. Hormonal
therapy is not indicated in the treatment of hormone
receptor-negative invasive breast cancer. Chemoprevention,
however, is widely used in the treatment of DCIS. In the
2000 Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) meta-analysis, compared to no adjuvant therapy,
5 years of tamoxifen was associated with a 41% relative
reduction in the risk of recurrence and a 34% relative
reduction in the risk of death in women with ER+/unknown
breast cancers [22]. In addition, tamoxifen was associated
with a 39% reduction in the annual risk of developing a
contralateral breast cancer in all ER-positive women.
In a pooled analysis of NSABP trials, where tamoxifen
was only given to all women above 50 years old, Swain et al.
also noticed that the use of adjuvant tamoxifen appeared to
reduce the risk for developing an ER-positive contralateral
breast cancer [18]. However, the same study showed that
30% of patients (8 of 27 patients) with ER-negative breast
tumors who were not on tamoxifen would develop an ER-
positive contralateral tumor, identifying a group which may4 ISRN Oncology
potentially beneﬁt from hormonal therapy. It is possible that
some of these ER-positive contralateral tumors may have
developed from an ER-positive DCIS associated with the ER-
negative invasive primary breast cancer.
In contrast to the studies in invasive breast cancer,
hormonal therapy does not appear to be eﬀective in chemo-
prevention in ER-negative DCIS. The NSABP B-24 trial
randomized women undergoing breast-sparing surgery and
radiation for DCIS, to adjuvant tamoxifen versus placebo
for 5 years, irrespective of ER status [23]. There was 39%
reduction of all ipsilateral and contralateral breast cancer
events (16.0% in the placebo arm versus 10.0% in the
tamoxifen arm; P = 0.0003) [24]. There was a 31% reduction
in the cumulative incidence of ipsilateral breast cancers
(11.1% with tamoxifen versus 7.7% with placebo, P = 0.02)
and 47% reduction in the cumulative incidence of contra-
lateral breast cancers (4.9% versus 2.3%, P = 0.01). Allred
et al. subsequently observed that the subgroups that appears
to have beneﬁted the most were ER-positive DCIS [25]. In
those subgroups tamoxifen was clearly eﬀective (relative risk
for all breast cancer events: 0.41, P = 0.0002). Signiﬁcant
clinical beneﬁt was achieved in both the ipsilateral and the
contralateral breast. In patients with ER-negative tumors,
a very modest beneﬁt was observed (relative risk for all
breast cancer events: 0.80, P = 0.51). Data from other
Tamoxifenpreventiontrialsalsoshowedareductioninbreast
cancer events that was restricted to ER-positive tumors [26].
Based upon the NSABP B-24 results, a new clinical trial for
patients with DCIS was initiated (NSABP B-35) [27]. Only
those patients with localized ER/PgR-positive DCIS will be
randomized to tamoxifen for ﬁve years or to anastrozole for
ﬁve years. The primary endpoint of the study is to evaluate
the eﬀectiveness of anastrozole compared to tamoxifen in
preventing subsequent breast cancer events.
In summary, the ﬁnding that ER/PgR-positive DCIS
coexists in a minority of patients with ER/PgR-negative
breast cancer, raises the issue of chemoprevention in this
cohort of patients. Clinically, hormonal therapy is not used
in the treatment of ER/PgR-negative invasive breast cancer
and chemoprevention has not had demonstrated to be of
beneﬁtinER/PgR-negativeinvasivebreastcancerorER/PgR-
negative DCIS. However, chemoprevention is routinely used
in ER/PgR-positive DCIS. The ﬁnding of ER/PgR-positive
DCIS in some patients with ER/PgR-negative breast cancer
may be clinically relevant and may necessitate a more careful
analysis of the tissue for this setting. Conﬁrmation of our
data by other institutions, by centralized immunohisto-
chemistry and reverse-transcription PCR (RT-PCR) [28]i s
warranted.
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